EFFICACY IN PATIENTS Anemia Transfusion erythrocyte asymptomatic TERMINAL CANCER STADIUM ON SOLID 30 DAYS survival in HOSPITAL DR.Sardjito YOGYAKARTA
ABSTRACT: Background. Anemia due to chronic disease is a condition experienced by many patients with cancer . Currently there is no standard reference that can be used for the practice of giving transfusions for asymptomatic anemic condition in the terminal stages of cancer. Giving blood transfusion in the treatment of anemic patients with end-stage cancer is still under debate , no agreement has been reached. Objective. To know wether there is any benefit of erythrocyte transfusions in aymptomatic anemia patients with terminal solid cancer for the survival in 30 days in DR.Sardjito hospital Yogyakarta. Method. Survival analysis study in the terminal stage of solid cancer patients with asymptomatic anemia with the inclusion and exclusion criteria will be divided into two groups : The group that carried out the transfusion and transfusion that was not done, to look at the efficacy of transfusions for survival in 30 days . Statistical analysis using the Statistical Product and Service Solutions ( SPSS ) 20.0 for Windows . Results. From the ninety nine samples of the study that were involved, with the mean age of patients 51.97 +- 12.3 years , comprising 45 male subjects ( 45 % ) and 54 women ( 54 % ) . Erythrocyte transfusion group ( 50 people ) and a group who did not receive transfusions of erythrocytes ( 49 ) . No difference in survival between the group of subjects who received a transfusion ( 40 ) compared with non- transfusion group ( 39 people ) at p = 0.96 . Conclusion. Based on the samples that involved in this study, it is conclude that no difference in survival between the group of subjects who received a transfusion of erythrocytes with not getting a transfusion in patients with terminal solid cancer with a note that there is still false negativity in this study due to the condition that the samples was not fully represent all the population research target.
ABSTRACT: Background. Anemia due to chronic disease is a condition experienced by many patients with cancer . Currently there is no standard reference that can be used for the practice of giving transfusions for asymptomatic anemic condition in the terminal stages of cancer. Giving blood transfusion in the treatment of anemic patients with end-stage cancer is still under debate , no agreement has been reached. Objective. To know wether there is any benefit of erythrocyte transfusions in aymptomatic anemia patients with terminal solid cancer for the survival in 30 days in DR.Sardjito hospital Yogyakarta. Method. Survival analysis study in the terminal stage of solid cancer patients with asymptomatic anemia with the inclusion and exclusion criteria will be divided into two groups : The group that carried out the transfusion and transfusion that was not done, to look at the efficacy of transfusions for survival in 30 days . Statistical analysis using the Statistical Product and Service Solutions ( SPSS ) 20.0 for Windows . Results. From the ninety nine samples of the study that were involved, with the mean age of patients 51.97 +- 12.3 years , comprising 45 male subjects ( 45 % ) and 54 women ( 54 % ) . Erythrocyte transfusion group ( 50 people ) and a group who did not receive transfusions of erythrocytes ( 49 ) . No difference in survival between the group of subjects who received a transfusion ( 40 ) compared with non- transfusion group ( 39 people ) at p = 0.96 . Conclusion. Based on the samples that involved in this study, it is conclude that no difference in survival between the group of subjects who received a transfusion of erythrocytes with not getting a transfusion in patients with terminal solid cancer with a note that there is still false negativity in this study due to the condition that the samples was not fully represent all the population research target.
